The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Open accessAbstract
BACKGROUND: mutation make up a small subgroup of those with metastatic pancreatic cancer. The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib has had antitumor activity in this population. METHODS: mutation and metastatic pancreatic cancer and disease that had not progressed during first-line platinum-based chemotherapy. Patients were randomly assigned, in a 3:2 ratio, to receive maintenance olaparib tablets (300 mg twice daily) or placebo. The primary end point was progression-free survival, which was assessed by blinded independent central review. RESULTS: Of the 3315 patients who underwent screening, 154 underwent randomization and were assigned to a trial intervention (92 to receive olaparib and 62 to receive placebo). The median progression-free survival was significantly longer in the olaparib group than in the placebo group (7.4 months vs. 3.8 months; hazard ratio for disease progression or death, 0.53; 95% confidence interval [CI], 0.35 to 0.82; P = 0.004). An interim analysis of overall survival, at a data maturity of 46%, showed no difference between the olaparib and placebo groups (median, 18.9 months vs. 18.1 months; hazard ratio for death, 0.91; 95% CI, 0.56 to 1.46; P = 0.68). There was no significant between-group difference in health-related quality of life, as indicated by the overall change from baseline in the global quality-of-life score (on a 100-point scale, with higher scores indicating better quality of life) based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (between-group difference, -2.47 points; 95% CI, -7.27 to 2.33). The incidence of grade 3 or higher adverse events was 40% in the olaparib group and 23% in the placebo group (between-group difference, 16 percentage points; 95% CI, -0.02 to 31); 5% and 2% of the patients, respectively, discontinued the trial intervention because of an adverse event. CONCLUSIONS: mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo. (Funded by AstraZeneca and others; POLO ClinicalTrials.gov number, NCT02184195.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“HRD targeted therapy with PARPi is mostly restricted to breast and ovarian cancer5, though its use for treating pancreatic cancer was recently approved by the FDA (US Food and Drug Administration)29.”
From Pan-cancer landscape of homologous recombination deficiency. (2020) · cites this paper as [29]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredIn the citing paper
“Finally, in late-stage PDAC with germline mutation in BRCA1 or BRCA2 (~7.5% of the patients), the PARP inhibitor olaparib could extend progression free survival but not overall survival (8).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [8]
In the citing paper
“a pivotal clinical trial in patients with PDAC and germline BRCA1/2 mutations established the benefit of administering an orally bioavailable PARP inhibitor on improved progression free survival (PFS). This led to the approval of targeted therapy in this setting87.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642
Self-citationEpidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269
Cited by
Sorted by citations
Mizrahi, J. D., Surana, R., Valle, J. W., & Shroff, R. T. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30974-0 · Cited by 2,559
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Park, W., Chawla, A., & O'Reilly, E. M. (2021) · JAMA · doi:10.1001/jama.2021.13027 · Cited by 2,040
Self-citationPancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Tempero, M. A., Malafa, M. P., Al-Hawary, M. M., Behrman, S. W., Benson, A. B., Cardin, D. B., Chiorean, E. G., Chung, V. M., Czito, B. G., Chiaro, M. D., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0017 · Cited by 1,356
Mosele, F., Remón, J., Mateo, J., Westphalen, C. B., Barlési, F., Lolkema, M. P., Normanno, N., Scarpa, A., Robson, M. E., Meric‐Bernstam, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.014 · Cited by 1,235
Pancreatic cancer stroma: an update on therapeutic targeting strategies
Hosein, A. N., Brekken, R. A., & Maitra, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0300-1 · Cited by 950
Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment
Wood, L. D., Canto, M. I., Jaffee, E. M., & Simeone, D. M. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.03.056 · Cited by 918
Targeting DNA damage response pathways in cancer
Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N., & Tarsounas, M. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00535-5 · Cited by 890
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 836
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Rose, M., Burgess, J. T., O'Byrne, K. J., Richard, D. J., & Bolderson, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564601 · Cited by 775
PARP and PARG inhibitors in cancer treatmentPreprint
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 693
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Conroy, T., Pfeiffer, P., Vilgrain, V., Lamarca, Á., Seufferlein, T. T. W., O'Reilly, E. M., Hackert, T., Golan, T., Prager, G. W., Haustermans, K. M., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.08.009 · Cited by 706
Self-citationSmall molecules, big impact: 20 years of targeted therapy in oncology
Bedard, P. L., Hyman, D. M., Davids, M. S., & Siu, L. L. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30164-1 · Cited by 637
Proteogenomic characterization of pancreatic ductal adenocarcinoma
Cao, L., Huang, C., Cui Zhou, D., Hu, Y., Lih, T. M., Savage, S. R., Krug, K., Clark, D. J., Schnaubelt, M., Chen, L., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.023 · Cited by 578
Poly(ADP-ribose) polymerase inhibition: past, present and future
Curtin, N. J., & Szabó, C. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0076-6 · Cited by 595
Pishvaian, M. J., Blais, E. M., Brody, J. R., Lyons, E. E., DeArbeloa, P., Hendifar, A. E., Mikhail, S., Chung, V. M., Sahai, V., Sohal, D. P. S., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30074-7 · Cited by 564
Pan-cancer landscape of homologous recombination deficiency.
Nguyen, L., W. M. Martens, J., Van Hoeck, A., & Cuppen, E. (2020) · Nature communications · doi:10.1038/s41467-020-19406-4 · Cited by 532
Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
Strickler, J. H., Satake, H., George, T. J., Yaeger, R., Hollebecque, A., Garrido-Laguna, I., Schuler, M., Burns, T. F., Coveler, A. L., Falchook, G. S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2208470 · Cited by 527
Accurate and efficient detection of gene fusions from RNA sequencing data
Uhrig, S., Ellermann, J., Walther, T., Burkhardt, P., Fröhlich, M., Hutter, B., Toprak, U. H., Neumann, O., Stenzinger, A., Scholl, C., et al. (2021) · Genome Research · doi:10.1101/gr.257246.119 · Cited by 526
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Dias, M. P., Moser, S. C., Ganesan, S., & Jonkers, J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00532-x · Cited by 544
Stoffel, E. M., Brand, R. E., & Goggins, M. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.012 · Cited by 565
Daly, M. B., Pilarski, R., Yurgelun, M. B. B., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A. M., Friedman, S., Garber, J. E., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0017 · Cited by 517
Stoop, T. F., Javed, A. A., Oba, A., Koerkamp, B. G., Seufferlein, T. T. W., Wilmink, J. W., & Besselink, M. G. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00261-2 · Cited by 601
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Grossberg, A. J., Chu, L. C. H., Deig, C. R., Fishman, E. K., Hwang, W. L., Maitra, A., Marks, D. L., Mehta, A., Nabavizadeh, N., Simeone, D. M., et al. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21626 · Cited by 500
Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance
Sherman, M. H., & Beatty, G. L. (2022) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031621-024600 · Cited by 501
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., Pintus, E., Sridhar, S. S., Bambury, R. M., Emmenegger, U., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214676 · Cited by 449
Therapeutic developments in pancreatic cancer
Hu, Z., & O'Reilly, E. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 438
Self-citationMosele, M. F., Westphalen, C. B., Stenzinger, A., Barlési, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.005 · Cited by 468
O'Reilly, E. M., Lee, J. W., Zalupski, M. M., Capanu, M., Park, J., Golan, T., Tahover, E., Lowery, M. A., Chou, J. F., Sahai, V., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02931 · Cited by 420
Self-citationFrom state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
Nevala-Plagemann, C., Hidalgo, M. M., & Garrido‐Laguna, I. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0281-6 · Cited by 403
Pancreatic Cancer: A Review of Current Treatment and Novel Therapies
Kolbeinsson, H. M., Chandana, S. R., Wright, G. P., & Chung, M. H. (2022) · Journal of Investigative Surgery · doi:10.1080/08941939.2022.2129884 · Cited by 433
Banerjee, S., Moore, K. N., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A. F., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00531-3 · Cited by 404
DNA Repair Pathways in Cancer Therapy and Resistance
Li, L.-Y., Guan, Y.-D., Chen, X.-S., Yang, J.-M., & Cheng, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.629266 · Cited by 383
“Several clinical trials using PARPi including Olaparib, Veliparib, Rucaparib (Table 1) as monotherapy for the treatment of patients with germline BRCA1/2 mutation tumors including advanced breast cancer, ovarian cancer, pancreatic cancer and prostate cancer presented significantly antitumor effect (Kaufman et al., 201…”
Nakamura, Y., Taniguchi, H., Ikeda, M., Bando, H., Kato, K., Morizane, C., Esaki, T., Komatsu, Y., Kawamoto, Y., Takahashi, N., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1063-5 · Cited by 373
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data
Connor, A. A., & Gallinger, S. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00418-1 · Cited by 369
KRAS mutation in pancreatic cancer
Luo, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.003 · Cited by 360
GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer
O’Kane, G. M., Grünwald, B. T., Jang, G.-H., Masoomian, M., Picardo, S., Grant, R. C., Denroche, R. E., Zhang, A., Wang, Y., Miller, J. K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3724 · Cited by 352
Cell death in pancreatic cancer: from pathogenesis to therapy
Chen, X., Zeh, H. J., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00486-6 · Cited by 344
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Qian, Y., Gong, Y., Fan, Z., Luo, G., Huang, Q., Deng, S., Cheng, H., Jin, K., Ni, Q., Yu, X., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00958-3 · Cited by 312
Primary and metastatic peritoneal surface malignancies
Guiral, D. C., Hübner, M., Alyami, M. S., Bhatt, A., Ceelen, W. P., Gléhen, O., Lordick, F., Ramsay, R. G., Sgarbura, O. A., der Speeten, K. V., et al. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00326-6 · Cited by 323
Metastatic Pancreatic Cancer: ASCO Guideline Update
Sohal, D. P. S., Kennedy, E. B., Cinar, P., Conroy, T., Copur, M. S., Crane, C. H., Garrido‐Laguna, I., Lau, M. W., Johnson, T. P., Krishnamurthi, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01364 · Cited by 313
Self-citationO'Hara, M. H., O'Reilly, E. M., Varadhachary, G., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G., Rahma, O., Lyman, J. P., Cabanski, C. R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30532-5 · Cited by 307
Self-citationNakamura, Y., Kawazoe, A., Lordick, F., Janjigian, Y. Y., & Shitara, K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00492-2 · Cited by 307
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
Zhu, H., Wei, M., Xu, J., Hua, J., Chen, L., Meng, Q., Zhang, Y., Liu, J., Zhang, B., Yu, X., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01167-9 · Cited by 263
Morice, P., Leary, A. F., Dolladille, C., Chrétien, B., Poulain, L., González-Martı́n, A., Moore, K. N., O'Reilly, E. M., Ray-Coquard, I. L., & Alexandre, J. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30360-4 · Cited by 263
Self-citationPrincipe, D. R., Underwood, P. W., Korc, M., Trevino, J. G., Munshi, H. G., & Rana, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.688377 · Cited by 273
Translational advances in pancreatic ductal adenocarcinoma therapy
Hosein, A. N., Dougan, S. K., Aguirre, A. J., & Maitra, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00349-2 · Cited by 255
Reiss, K. A., Mick, R., O’Hara, M. H., Teitelbaum, U. R., Karasic, T. B., Schneider, C. J., Cowden, S., Southwell, T., Romeo, J., Izgur, N., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00003 · Cited by 258
The Immune Microenvironment in Pancreatic Cancer
Huber, M., Brehm, C. U., Gress, T. M., Buchholz, M., Alhamwe, B. A., von Strandmann, E. P., Slater, E. P., Bartsch, J. W., Bauer, C. A., & Lauth, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197307 · Cited by 250
Kindler, H. L., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J. O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01604 · Cited by 244
Self-citationChristenson, E. S., Jaffee, E. M., & Azad, N. S. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30795-8 · Cited by 245
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Peyraud, F., & Italiano, A. (2020) · Cancers · doi:10.3390/cancers12061502 · Cited by 245
Park, W., Chen, J., Chou, J. F., Varghese, A. M., Yu, K. H., Wong, W., Capanu, M., Balachandran, V. P., McIntyre, C. A., Dika, I. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0418 · Cited by 247
Self-citationBiomarker-Guided Development of DNA Repair Inhibitors
Cleary, J. M., Aguirre, A. J., Shapiro, G. I., & D’Andrea, A. D. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.035 · Cited by 239
Clinical cancer genomic profiling
Chakravarty, D., & Solit, D. B. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00338-8 · Cited by 241
Circulating tumor DNA: current challenges for clinical utility
Dang, D. K., & Park, B. H. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154941 · Cited by 239
Wang, Q., Gumus, Z. H., Colarossi, C., Memeo, L., Wang, X., Kong, C. Y., & Boffetta, P. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.10.002 · Cited by 239
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
Eikesdal, H. P., Yndestad, S., Elzawahry, A., Llop‐Guevara, A., Gilje, B., Blix, E. S., Espelid, H., Lundgren, S., Geisler, J., Vagstad, G., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.009 · Cited by 228
Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants
Momozawa, Y., Sasai, R., Usui, Y., Shiraishi, K., Iwasaki, Y., Taniyama, Y., Parsons, M. T., Mizukami, K., Sekine, Y., Hirata, M., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0476 · Cited by 230
Neoadjuvant Treatment in Pancreatic Cancer
Oba, A., Ho, F., Bao, Q. R., Al-Musawi, M. H., Schulick, R. D., & Chiaro, M. D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00245 · Cited by 219
The pancreatic cancer genome revisited
Hayashi, A., Hong, J., & Iacobuzio-Donahue, C. A. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00463-z · Cited by 211
An update on treatment options for pancreatic adenocarcinoma
Lambert, A., Schwarz, L., Borbath, I., Henry, A., Laethem, J. V., Malka, D., Ducreux, M. P., & Conroy, T. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919875568 · Cited by 222
Synthetic Lethality in Cancer Therapeutics: The Next Generation
Setton, J. S., Zinda, M. J., Riaz, N., Durocher, D., Zimmermann, M., Koehler, M. T., Reis-Filho, J. S., & Powell, S. N. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1503 · Cited by 214
Treatment landscape of metastatic pancreatic cancer
Dosso, S. D., Siebenhüner, A. R., Winder, T., Meisel, A., Fritsch, R., Astaras, C., Szturz, P., & Borner, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102180 · Cited by 212
Swisher, E. M., Kwan, T. T., Oza, A. M., Tinker, A. V., Ray-Coquard, I. L., Oaknin, A., Coleman, R. L., Aghajanian, C. A., Konecny, G. E., O’Malley, D. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22582-6 · Cited by 209
DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives
Perkhofer, L., Gout, J., Roger, É., de Almeida, F. K., Simões, C., Wiesmüller, L., Seufferlein, T. T. W., & Kleger, A. (2020) · Gut · doi:10.1136/gutjnl-2019-319984 · Cited by 207
Wattenberg, M. M., Asch, D., Yu, S., O'Dwyer, P. J., Domchek, S. M., Nathanson, K. L., Rosen, M. A., Beatty, G. L., Siegelman, E. S., & Reiss, K. A. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0582-7 · Cited by 211
New clinical trial design in precision medicine: discovery, development and direction
Duan, X.-P., Qin, B., Jiao, X., Liu, K., Wang, Z., & Zang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01760-0 · Cited by 225
Tobalina, L., Armenia, J., Irving, E., O’Connor, M. J., & Forment, J. V. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.470 · Cited by 196
Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma
Philip, P. A., Azar, I., Xiu, J., Hall, M. J., Hendifar, A. E., Lou, E., Hwang, J. J., Gong, J., Feldman, R., Ellis, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3581 · Cited by 191
Self-citationSmall molecule inhibitors targeting the cancers
Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022) · MedComm · doi:10.1002/mco2.181 · Cited by 212
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing
Pujol, P., Barberis, M. C. P., Beer, P., Friedman, E., Piulats, J. M., Capoluongo, E., García‐Foncillas, J., Ray-Coquard, I. L., Penault-Llorca, F. M., Foulkes, W. D., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2020.12.023 · Cited by 187
Self-citationPARP Inhibition in Cancer: An Update on Clinical Development
Sachdev, E., Tabatabai, R., Roy, V. Y., Rimel, B. J., & Mita, M. M. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00680-2 · Cited by 190
Lloyd, R. L., Wijnhoven, P. W. G., Ramos‐Montoya, A., Wilson, Z., Illuzzi, G., Falenta, K., Jones, G. N., James, N. H., Chabbert, C. D., Stott, J., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1328-y · Cited by 185
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
Topatana, W., Juengpanich, S., Li, S., Cao, J., Hu, J., Lee, J., Suliyanto, K., Ma, D., Zhang, B., Chen, M., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00956-5 · Cited by 193
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
Salvador-Barberó, B., Álvarez‐Fernández, M., Zapatero‐Solana, E., Bakkali, A. E., Menéndez, C., Lopez-Casas, P. P., Domenico, T. D., Xie, T., VanArsdale, T. L., Shields, D. J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.01.007 · Cited by 181
Sokol, E. S., Pavlick, D. C., Khiabanian, H., Frampton, G. M., Ross, J. S., Gregg, J. P., Lara, P. N., Oesterreich, S., Agarwal, N., Necchi, A., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00345 · Cited by 182
Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
Bradbury, A., Hall, S., Curtin, N. J., & Drew, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107450 · Cited by 180
Germline Genetic Testing After Cancer Diagnosis
Kurian, A. W., Abrahamse, P. H., Furgal, A. K. C., Ward, K. C., Hamilton, A. S., Hodan, R., Tocco, R. S., Liu, L., Berek, J. S., Hoang, L., et al. (2023) · JAMA · doi:10.1001/jama.2023.9526 · Cited by 178
Schram, A. M., Odintsov, I., Espinosa-Cotton, M., Khodos, I., Sisso, W. J., Mattar, M. S., Lui, A. J. W., Vojnic, M., Shameem, S. H., Chauhan, T., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1119 · Cited by 178
Self-citationMarkham, M. J., WACHTER, K., Agarwal, N., Bertagnolli, M. M., Chang, S. M., Dale, W., Diefenbach, C., Galindo, C. R., George, D. J., Gilligan, T. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03141 · Cited by 181
Nakamura, K., Zhu, Z., Roy, S., Jun, E., Han, H., Muñoz, R. M., Nishiwada, S., Sharma, G. G., Cridebring, D., Zenhausern, F., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.06.090 · Cited by 174
Self-citationDNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
Jurkovičová, D., Neophytou, C. M., Gašparović, A. Č., & Gonçalves, A. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314672 · Cited by 175
Unique roles of rare variants in the genetics of complex diseases in humans
Momozawa, Y., & Mizukami, K. (2021) · Journal of Human Genetics · doi:10.1038/s10038-020-00845-2 · Cited by 161
Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer
Dreyer, S. B., Upstill‐Goddard, R., Paulus-Hock, V., Paris, C., Lampraki, E.-M., Dray, E. V., Serrels, B., Caligiuri, G., Rebus, S., Plenker, D., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.09.043 · Cited by 165
Shu, Y., He, X., Liu, Y., Wu, P., & Zhang, Q. (2022) · Clinical Epidemiology · doi:10.2147/clep.s365513 · Cited by 163
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
Singh, R., & O'Reilly, E. M. (2020) · Drugs · doi:10.1007/s40265-020-01304-0 · Cited by 158
Self-citationGolan, T., O'Kane, G. M., Denroche, R. E., Raitses‐Gurevich, M., Grant, R. C., Holter, S., Wang, Y., Zhang, A. X. W., Jang, G. H., Stossel, C., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.01.220 · Cited by 157
Self-citationTherapeutic Implications of Germline Testing in Patients With Advanced Cancers
Stadler, Z. K., Maio, A., Chakravarty, D., Kemel, Y. M., Sheehan, M. R., Salo‐Mullen, E. E., Tkachuk, K. A., Fong, C. J., Nguyen, B., Erakky, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03661 · Cited by 156
Self-citationSawhney, M., Calderwood, A. H., Thosani, N. C., Rebbeck, T. R., Wani, S. B., Canto, M. I., Fishman, D. S., Golan, T., Hidalgo, M. M., Kwon, R. S., et al. (2022) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2021.12.001 · Cited by 158
Self-citationRicciuti, B., Recondo, G., Spurr, L. F., Li, Y. Y., Lamberti, G., Venkatraman, D., Umeton, R., Cherniack, A. D., Nishino, M., Sholl, L. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3529 · Cited by 154
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
Wei, D., Wang, L., Zuo, X., Maitra, A., & Bresalier, R. S. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2098 · Cited by 177
Barriers and opportunities for gemcitabine in pancreatic cancer therapy
Beutel, A. K., & Halbrook, C. J. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00331.2022 · Cited by 150
Reiss, K. A., Mick, R., Teitelbaum, U. R., O’Hara, M. H., Schneider, C. J., Massa, R. C., Karasic, T. B., Tondon, R., Onyiah, C., Gosselin, M. K., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00369-2 · Cited by 156
Hu, H.-F., Ye, Z., Qin, Y., Xu, X.-W., Yu, X.-J., Zhuo, Q.-F., & Ji, S.-R. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00584-2 · Cited by 149
Prostate cancer and PARP inhibitors: progress and challenges
Teyssonneau, D., Margot, H., Cabart, M., Anonnay, M., Sargos, P., Vuong, N., Soubeyran, I., Sévenet, N., & Roubaud, G. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01061-x · Cited by 154
Perez, V. M., Kearney, J. F., & Yeh, J. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.751311 · Cited by 143
Prospects for combining immune checkpoint blockade with PARP inhibition
Li, A., Yi, M., Qin, S., Chu, Q., Luo, S., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0784-8 · Cited by 143
Metadata
- Authors
- Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., Reinacher-Schick, A., Tortora, G., Algül, H., O’Reilly, E. M., McGuinness, D., Cui, K. Y., Schlienger, K., Locker, G. Y., & Kindler, H. L.
- Affiliations
- Tel Aviv University (IL)
- From the Oncology Institute, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (T.G.); Hôpital Beaujon (Assistance Publique–Hôpitaux de Paris), Clichy, and University Paris VII, Paris (P.H.); IRCCS Ospedale San Raffaele Scientific Institute, Milan (M.R.), Azienda Ospedaliera Universitaria Integrata Verona, Verona (G.T.), and Fondazione Policlinico Universitario Gemelli IRCCS, Rome (G.T.) — all in Italy; University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium (E.V.C.); Vall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-07-25
- Volume
- 381
- Issue
- 4
- Pages
- 317-327
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6810605
- OpenAlex
- W2947826965
- Cited by
- 2,302
- References
- 24
- Citations by year
- 2026: 195 · 2025: 268 · 2024: 292 · 2023: 312 · 2022: 412 · 2021: 452 · 2020: 299 · 2019: 66
- FWCI
- 129.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, cc-by-nc-nd)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- AstraZeneca (NA)
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc (NA)
- NIH/NCI Cancer Center Support Grant (P30-17 CA008748)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- olaparib, PARP inhibitors, germline BRCA mutation, metastatic pancreatic cancer, maintenance therapy, progression-free survival, overall survival, quality of life, adverse events, platinum-based chemotherapy, PARP inhibitor resistance, DNA repair deficiency, targeted therapy, interim analysis, predictive biomarkers, treatment discontinuation, health-related quality of life
- MeSH terms
- Progression-Free Survival, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Double-Blind Method, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Pancreatic Neoplasms, Phthalazines, Piperazines, Germ-Line Mutation, Genes, BRCA1, Genes, BRCA2, Kaplan-Meier Estimate, Maintenance Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
